Cytokine Release Syndrome: Current Perspectives

被引：119

作者：

Murthy, Hemant ^{[1
,2
]}

Iqbal, Madiha ^{[1
,2
]}

Chavez, Julio C. ^{[3
]}

Kharfan-Dabaja, Mohamed A. ^{[1
,2
]}

机构：

[1] Mayo Clin, Div Hematol Oncol, 4500 San Pablo Rd,Mangurian Bdg 3rd Floor, Jacksonville, FL 32224 USA

[2] Mayo Clin, Blood & Marrow Transplantat Program, 4500 San Pablo Rd,Mangurian Bdg 3rd Floor, Jacksonville, FL 32224 USA

[3] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA

来源：

IMMUNOTARGETS AND THERAPY | 2019年 / 8卷

关键词：

cytokine release syndrome; chimeric antigen receptor T-cell therapy; T-CELL THERAPY; A(3) ADENOSINE RECEPTOR; ANTIBODY; IL-6; MANAGEMENT; SAFETY; REMISSIONS; TOXICITIES; BIOMARKERS; SERUM;

D O I：

10.2147/ITT.S202015

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Chimeric antigen receptor T cell (CART) therapy represents a novel and a paradigm-shifting approach to treating cancer. Recent clinical successes have widened the applicability of CD19 CART cells for the treatment of relapsed/refractory B-cell NHL, namely tisagenleclucel and axicabtagene ciloleucel. Tisagenleclucel is also approved for relapsed and/or refractory B-ALL up to age 25. CART therapy is associated with unique and potentially life-threatening toxicities, notably cytokine release syndrome (CRS). A better understanding of the pathogenesis of CRS is crucial to ensure proper management. In this review, CRS definitions, profiles, risk factors and grading systems are discussed. Finally, current and novel investigational approaches and therapies for CRS are summarized.

引用

页码：43 / 52

页数：10

共 50 条

[31] AntineoplasticsMucositis, cytokine release syndrome and lack of efficacy
Reactions Weekly, 2024, 2004 (1) : 55 - 55
[32] Cytokine release syndrome after bronchoalveolar lavage
Guerriero, Margaret
Ally, Feras
Loeb, Keith R.
Nair, Viswam S.
BMC PULMONARY MEDICINE, 2023, 23 (01)
[33] Tocilizumab Use in Children with Cytokine Release Syndrome
Raj, Revathi
Uppuluri, Ramya
Venkateswaran, V. S.
INDIAN PEDIATRICS, 2021, 58 (02) : 186 - 187
[34] IDENTIFYING AND TREATING CYTOKINE RELEASE SYNDROME.
Miller, Victoria
Pandey, Prasamsa
ONCOLOGY NURSING FORUM, 2017, 44 (02)
[35] Axicabtagene ciloleucelGrade 2 cytokine release syndrome
Reactions Weekly, 2024, 2016 (1) : 77 - 77
[36] Update on Pediatric Cytokine Release Syndrome (CRS)
Pao, Maryland
PSYCHO-ONCOLOGY, 2023, 32 : 25 - 25
[37] Tocilizumab Use in Children with Cytokine Release Syndrome
Revathi Raj
Ramya Uppuluri
Venkateswaran VS
Indian Pediatrics, 2021, 58 : 186 - 187
[38] Cytokine release syndrome treatment and management flowchart
Carr, Jaydine
Berzosa, Sonia
BONE MARROW TRANSPLANTATION, 2019, 54 : 198 - 198
[39] Management Principles Associated With Cytokine Release Syndrome
Baer, Brittney
Dudley, Channing Vail
Simons, Rhea Micci
SEMINARS IN ONCOLOGY NURSING, 2019, 35 (05)
[40] Alstrom syndrome: current perspectives
Alvarez-Satta, Maria
Castro-Sanchez, Sheila
Valverde, Diana
APPLICATION OF CLINICAL GENETICS, 2015, 8 : 171 - 179

← 1 2 3 4 5 →